MV 2101
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Miravant Medical Technologies
- Class Cardiovascular therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Vascular graft occlusion
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-graft-occlusion in USA
- 12 Jul 2004 Miravant and Guidant have entered into an agreement to co-develop PhotoPoint technology
- 23 Dec 2003 MV 2101 has received orphan drug status in the USA for the prevention of graft occlusion in patients undergoing dialysis